NEOTIGASON 25 MG

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Δραστική ουσία:

ACITRETIN

Διαθέσιμο από:

ABIC MARKETING LTD, ISRAEL

Φαρμακολογική κατηγορία (ATC):

D05BB02

Φαρμακοτεχνική μορφή:

CAPSULES

Σύνθεση:

ACITRETIN 25 MG

Οδός χορήγησης:

PER OS

Τρόπος διάθεσης:

Required

Κατασκευάζεται από:

ACTAVIS GROUP PTC EHF, ICELAND

Θεραπευτική ομάδα:

ACITRETIN

Θεραπευτική περιοχή:

ACITRETIN

Θεραπευτικές ενδείξεις:

Severe disorders of keratinization such as erythrodermic psoriasis local or generalized pustular psoriasis congenital ichthyosis pityriasis rubra pilaris darier's disease.

Ημερομηνία της άδειας:

2017-01-31

Φύλλο οδηγιών χρήσης

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
▼THIS MEDICINAL PRODUCT IS SUBJECT TO ADDITIONAL MONITORING. THIS
WILL ALLOW QUICK
IDENTIFICATION OF NEW SAFETY INFORMATION. HEALTHCARE PROFESSIONALS ARE
ASKED TO
REPORT ANY SUSPECTED ADVERSE REACTIONS. SEE SECTION “UNDESIRABLE
EFFECTS” FOR HOW TO
REPORT ADVERSE REACTIONS.
NEOTIGASON 10MG AND 25MG CAPSULES
*************************************************************************************
1
NAME OF THE MEDICINAL PRODUCT
Neotigason 10mg Capsules
Neotigason25mg Capsules
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
10 mg Capsules:
Each capsule, contains Acitretin 10 mg
25 mg Capsules:
Each capsule, contains Acitretin 25 mg
Excipients with known affect: Glucose (see section _4.3
Contraindications_).
This medicine contains less than 1 mmol sodium (23 mg) per capsule,
that is to say
essentially ‘sodium-free’.
For a full list of excipients, see section _6.1 List of excipients_.
3
PHARMACEUTICAL FORM
Capsules for oral administration
10 mg Capsules:
Hard gelatin capsules with white body and brown cap with “10”
printed in black on the
body, containing 10 mg acitretin.
25mg Capsules:
Hard gelatin capsules with yellow body and brown cap with “25”
printed in black on the
body, containing 25 mg acitretin.
Neotigason Capsules 10mg, 25mg, SPC, 02-2020, HH, Notification
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Severe disorders of keratinization such as erythrodermic psoriasis
local or generalized or
pustular psoriasis congenital ichthyosis pityriasis rubra pilaris
darier's disease.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Neotigason should only be prescribed by physicians who are experienced
in the use of
systemic retinoids and understand the risk of teratogenicity
associated with acitretin
therapy (see Section 4.6).
The capsules should be taken once daily with meals or with milk.
There is a wide variation in the absorption and rate of metabolism of
Neotigason. This
necessitates individual adjustment of dosage. For this reason the
following dosage
recommendations can